Sezzle Inc. (NASDAQ: SEZL,) ( Sezzle or Company) // Purpose-driven digital payment platform, Sezzle, today announced that the Company's Board of Directors (the "Board”) declared a six-for-one split of ...

Market Research Report for 2025 delivers a comprehensive analysis of the industry's progress, examining both historical trends and the current market landscape. It provides key insights into ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease that affects red blood cells, causing symptoms like dark urine, fatigue, and unexplained bruising. Early diagnosis is challenging due to ...

Five new agents to treat gMG have been approved, including three complement inhibitors -- eculizumab (Soliris), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq) – and two neonatal FcRn ...

Eculizumab and ravulizumab are both safe and effective and prevent relapses in patients with anti-AQP4 antibody-positive NMOSD with more than 95% of patients staying relapse-free in the follow-up ...

With the rising incidence of cancer in India, AstraZeneca India’s breast cancer medicine trastuzumab deruxtecan (sold under the brand name Enhertu) emerged as the highest-selling new drug brand ...

Eculizumab has been used in the treatment of TA-TMA, and several studies have confirmed the benefit of Eculizumab in patients with TA-TMA. However, the results remain controversial. We conducted a ...